Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOTOX for Crow's Feet Lines in China
NCT02195687Phase 3Completed
- Sponsor
- Allergan
- Start
- Sep 2014
- Primary completion
- Feb 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial comparing BOTOX with Placebo (2 arms). Primary endpoint: Percentage of Subjects Achieving None or Mild on the Investigator's Assessment of the Severity of Crow's Feet Lines (CFL) at Maximum Smile Using the Facial Wrinkle Scale-Asian (FWS-A) at Day 30. Started Sep 2014; status: completed.
02
Drugs
onabotulinumtoxinA
Beyond the preview
Go deeper on NCT02195687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02195687.